- Primary Renal Leiomyosarcoma Presenting with Subcutaneous and Osseous Metastases: Staging and Follow-Up with 18F-FDG PET/CT
-
Makis W, Brimo F, Probst S
- KMID: 2407304
- Nucl Med Mol Imaging.
- 2018 Feb;52(1):69-73.
- doi: 10.1007/s13139-016-0467-0
A 60 year old woman who presented with multiple small subcutaneous nodules in the upper back and arms, was referred for an [¹â¸F] fluoro-2-deoxy-D-glucose (¹â¸F-FDG) positron emission tomography/computed tomography (PET/CT)... -
- CITED
-
- Close
- SHARE
-
- Close
- Systemic Lupus Erythematosus Associated Pitfalls on ¹â¸F-FDG PET/CT: Reactive Follicular Hyperplasia, Kikuchi-Fujimoto Disease, Inflammation and Lymphoid Hyperplasia of the Spleen Mimicking Lymphoma
-
Makis W, Ciarallo A, Milene GV, Probst S
- KMID: 2407305
- Nucl Med Mol Imaging.
- 2018 Feb;52(1):74-79.
- doi: 10.1007/s13139-017-0471-z
Systemic lupus erythematosus (SLE) is associated with a variety of inflammatory processes that can affect the lymph nodes, brain, kidneys, and spleen. We present two patients with SLE in whom... -
- CITED
-
- Close
- SHARE
-
- Close
- Outcomes and Factors Associated with Completion of Radium‑223 Therapy
-
Liu R, Juwara L, Ferrario C, Probst S
- KMID: 2534410
- Nucl Med Mol Imaging.
- 2022 Oct;56(5):228-235.
- doi: 10.1007/s13139-022-00760-8
Purpose Radium-223 has been demonstrated in clinical trials to improve survival in castration-resistant prostate cancer (CRPC) patients with bone metastases. However, its performance in routine use remains to be fully... -
- CITED
-
- Close
- SHARE
-
- Close
- Composite Cutaneous Lymphoma (Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorder) in a Patient with Rheumatoid Arthritis Treated with Methotrexate: Staging and Evaluation of Response to Therapy with ¹â¸F-FDG PET/CT
-
Makis W, Ciarallo A, Wang B, Gonzalez-Verdecia M, Probst S
- KMID: 2396586
- Nucl Med Mol Imaging.
- 2017 Sep;51(3):261-265.
- doi: 10.1007/s13139-016-0463-4
A 67 year old woman with a 10 year history of rheumatoid arthritis (RA) treated with methotrexate and prednisone, presented with a 2 year history of worsening multiple cutaneous plaques... -
- CITED
-
- Close
- SHARE
-
- Close
- Interval Changes in PSMA PET/CT During Radium‑223 Therapy for Metastatic Bone Disease from Castration‑Resistant Prostate Cancer
-
Probst S, Bjartell A, Anand A, Skamene T, Ferrario C
- KMID: 2532369
- Nucl Med Mol Imaging.
- 2022 Aug;56(4):188-195.
- doi: 10.1007/s13139-022-00754-6
Background Radium-223, an alpha-emitting therapeutic radiopharmaceutical, prolongs overall survival (OS) in patients with symptomatic bone-predominant metastatic castration-resistant prostate cancer (mCRPC). PSMA PET/CT is a molecular imaging tool for whole-body imaging... -
- CITED
-
- Close
- SHARE
-
- Close
